- Checkpoint Therapeutics expects to report top-line results before year-end, which could determine if Cosibelimab is ready for regulatory submission that could lead to an approval and commercial launch in 2023.
- Volatility has the share price, which is making big moves in both directions as we move closer to year-end. Investors need to have a game plan.
- I believe the recent pullback could be a great opportunity for me to buy ahead of this incredibly potent catalyst.
For further details see:
Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout